Literature DB >> 23917080

ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.

Sharon E Johnatty1, Jonathan Beesley, Bo Gao, Xiaoqing Chen, Yi Lu, Matthew H Law, Michelle J Henderson, Amanda J Russell, Ellen L Hedditch, Catherine Emmanuel, Sian Fereday, Penelope M Webb, Ellen L Goode, Robert A Vierkant, Brooke L Fridley, Julie M Cunningham, Peter A Fasching, Matthias W Beckmann, Arif B Ekici, Estrid Hogdall, Susanne K Kjaer, Allan Jensen, Claus Hogdall, Robert Brown, Jim Paul, Sandrina Lambrechts, Evelyn Despierre, Ignace Vergote, Jenny Lester, Beth Y Karlan, Florian Heitz, Andreas du Bois, Philipp Harter, Ira Schwaab, Yukie Bean, Tanja Pejovic, Douglas A Levine, Marc T Goodman, Michael E Camey, Pamela J Thompson, Galina Lurie, Joellen Shildkraut, Andrew Berchuck, Kathryn L Terry, Daniel W Cramer, Murray D Norris, Michelle Haber, Stuart MacGregor, Anna deFazio, Georgia Chenevix-Trench.   

Abstract

OBJECTIVE: ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance. We comprehensively evaluated this gene and flanking regions for an association with clinical outcome in epithelial ovarian cancer (EOC).
METHODS: The best candidates from fine-mapping analysis of 21 ABCB1 SNPs tagging C1236T (rs1128503), G2677T/A (rs2032582), and C3435T (rs1045642) were analysed in 4616 European invasive EOC patients from thirteen Ovarian Cancer Association Consortium (OCAC) studies and The Cancer Genome Atlas (TCGA). Additionally we analysed 1,562 imputed SNPs around ABCB1 in patients receiving cytoreductive surgery and either 'standard' first-line paclitaxel-carboplatin chemotherapy (n=1158) or any first-line chemotherapy regimen (n=2867). We also evaluated ABCB1 expression in primary tumours from 143 EOC patients. RESULT: Fine-mapping revealed that rs1128503, rs2032582, and rs1045642 were the best candidates in optimally debulked patients. However, we observed no significant association between any SNP and either progression-free survival or overall survival in analysis of data from 14 studies. There was a marginal association between rs1128503 and overall survival in patients with nil residual disease (HR 0.88, 95% CI 0.77-1.01; p=0.07). In contrast, ABCB1 expression in the primary tumour may confer worse prognosis in patients with sub-optimally debulked tumours.
CONCLUSION: Our study represents the largest analysis of ABCB1 SNPs and EOC progression and survival to date, but has not identified additional signals, or validated reported associations with progression-free survival for rs1128503, rs2032582, and rs1045642. However, we cannot rule out the possibility of a subtle effect of rs1128503, or other SNPs linked to it, on overall survival.
© 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCB1; Chemotherapy; Genetics; Outcome; Ovarian cancer; Polymorphisms

Mesh:

Substances:

Year:  2013        PMID: 23917080      PMCID: PMC3795832          DOI: 10.1016/j.ygyno.2013.07.107

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Efficiency and power in genetic association studies.

Authors:  Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler
Journal:  Nat Genet       Date:  2005-10-23       Impact factor: 38.330

2.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix.

Authors:  J Li; L Ji
Journal:  Heredity (Edinb)       Date:  2005-09       Impact factor: 3.821

3.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

4.  MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes.

Authors:  Yun Li; Cristen J Willer; Jun Ding; Paul Scheet; Gonçalo R Abecasis
Journal:  Genet Epidemiol       Date:  2010-12       Impact factor: 2.135

5.  Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

Authors:  Michelle Haber; Janice Smith; Sharon B Bordow; Claudia Flemming; Susan L Cohn; Wendy B London; Glenn M Marshall; Murray D Norris
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

Review 6.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research.

Authors:  G D Leschziner; T Andrew; M Pirmohamed; M R Johnson
Journal:  Pharmacogenomics J       Date:  2006-09-12       Impact factor: 3.550

7.  Quantification of the completeness of follow-up.

Authors:  Taane G Clark; Douglas G Altman; Bianca L De Stavola
Journal:  Lancet       Date:  2002-04-13       Impact factor: 79.321

8.  Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.

Authors:  Sharon Marsh; Jim Paul; Cristi R King; Gillian Gifford; Howard L McLeod; Robert Brown
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

Review 9.  Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

Authors:  Zuben E Sauna; Chava Kimchi-Sarfaty; Suresh V Ambudkar; Michael M Gottesman
Journal:  Cancer Res       Date:  2007-10-15       Impact factor: 12.701

10.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Authors:  Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman
Journal:  Genome Biol       Date:  2002-06-18       Impact factor: 13.583

View more
  26 in total

1.  Influence of TS and ABCB1 gene polymorphisms on survival outcomes of 5‑FU-based chemotherapy in a Chinese population of advanced gastric cancer patients.

Authors:  Jun Chen; Xueming Ying; Ling Zhang; Xiaojun Xiang; Jianping Xiong
Journal:  Wien Klin Wochenschr       Date:  2017-01-10       Impact factor: 1.704

2.  CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers.

Authors:  Qingyang Xiao; Stefania Koutsilieri; Despoina-Christina Sismanoglou; Volker M Lauschke
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-17       Impact factor: 4.322

3.  MDR1 polymorphisms have an impact on the prognosis of Chinese diffuse large B cell lymphoma patients.

Authors:  Ying Ni; Guangli Yin; Zhengrui Xiao; Lei Fan; Li Wang; Yujie Wu; Hanxin Wu; Sixuan Qian; Wei Xu; Jianyong Li; Kourong Miao; Hairong Qiu
Journal:  Tumour Biol       Date:  2015-08-19

4.  Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.

Authors:  Rachel Eyre; Ian Harvey; Katherine Stemke-Hale; Thomas W J Lennard; Alison Tyson-Capper; Annette P Meeson
Journal:  Tumour Biol       Date:  2014-07-04

5.  P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Authors:  Chengqiong Mao; Yan Zhao; Fang Li; Zibo Li; Shaomin Tian; Waldemar Debinski; Xin Ming
Journal:  J Control Release       Date:  2018-08-04       Impact factor: 9.776

6.  Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Authors:  Leda Severi; Lorena Losi; Sergio Fonda; Laura Taddia; Gaia Gozzi; Gaetano Marverti; Fulvio Magni; Clizia Chinello; Martina Stella; Jalid Sheouli; Elena I Braicu; Filippo Genovese; Angela Lauriola; Chiara Marraccini; Alessandra Gualandi; Domenico D'Arca; Stefania Ferrari; Maria P Costi
Journal:  Front Pharmacol       Date:  2018-05-08       Impact factor: 5.810

7.  ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.

Authors:  Ellen L Hedditch; Bo Gao; Amanda J Russell; Yi Lu; Catherine Emmanuel; Jonathan Beesley; Sharon E Johnatty; Xiaoqing Chen; Paul Harnett; Joshy George; Rebekka T Williams; Claudia Flemming; Diether Lambrechts; Evelyn Despierre; Sandrina Lambrechts; Ignace Vergote; Beth Karlan; Jenny Lester; Sandra Orsulic; Christine Walsh; Peter Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Keitaro Matsuo; Satoyo Hosono; Toru Nakanishi; Yasushi Yatabe; Tanja Pejovic; Yukie Bean; Florian Heitz; Philipp Harter; Andreas du Bois; Ira Schwaab; Estrid Hogdall; Susan K Kjaer; Allan Jensen; Claus Hogdall; Lene Lundvall; Svend Aage Engelholm; Bob Brown; James Flanagan; Michelle D Metcalf; Nadeem Siddiqui; Thomas Sellers; Brooke Fridley; Julie Cunningham; Joellen Schildkraut; Ed Iversen; Rachel P Weber; Andrew Berchuck; Ellen Goode; David D Bowtell; Georgia Chenevix-Trench; Anna deFazio; Murray D Norris; Stuart MacGregor; Michelle Haber; Michelle J Henderson
Journal:  J Natl Cancer Inst       Date:  2014-06-23       Impact factor: 13.506

8.  Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis.

Authors:  Quanyao Chen; Wanlong Lin; Jianhui Yang; Min Lin; Xiuxian Lin; Yiyin Weng; Yao Chen
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

9.  Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.

Authors:  Michael C J Quinn; Karen McCue; Stuart MacGregor; Georgia Chenevix-Trench; Wei Shi; Sharon E Johnatty; Jonathan Beesley; Andrew Civitarese; Tracy A O'Mara; Dylan M Glubb; Jonathan P Tyrer; Sebastian M Armasu; Jue-Sheng Ong; Puya Gharahkhani; Yi Lu; Bo Gao; Ann-Marie Patch; Peter A Fasching; Matthias W Beckmann; Diether Lambrechts; Ignace Vergote; Digna R Velez Edwards; Alicia Beeghly-Fadiel; Javier Benitez; Maria J Garcia; Marc T Goodman; Thilo Dörk; Matthias Dürst; Francesmary Modugno; Kirsten Moysich; Andreas du Bois; Jacobus Pfisterer; Klaus Bauman; Beth Y Karlan; Jenny Lester; Julie M Cunningham; Melissa C Larson; Bryan M McCauley; Susanne K Kjaer; Allan Jensen; Claus K Hogdall; Estrid Hogdall; Joellen M Schildkraut; Marjorie J Riggan; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Line Bjorge; Penelope M Webb; Michael Friedlander; Tanja Pejovic; Melissa Moffitt; Rosalind Glasspool; Taymaa May; Gabrielle E V Ene; David G Huntsman; Michelle Woo; Michael E Carney; Samantha Hinsley; Florian Heitz; Sian Fereday; Catherine J Kennedy; Stacey L Edwards; Stacey J Winham; Anna deFazio; Paul D P Pharoah; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-23       Impact factor: 4.090

10.  Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.

Authors:  Sharon E Johnatty; Jonathan P Tyrer; Siddhartha Kar; Jonathan Beesley; Yi Lu; Bo Gao; Peter A Fasching; Alexander Hein; Arif B Ekici; Matthias W Beckmann; Diether Lambrechts; Els Van Nieuwenhuysen; Ignace Vergote; Sandrina Lambrechts; Mary Anne Rossing; Jennifer A Doherty; Jenny Chang-Claude; Francesmary Modugno; Roberta B Ness; Kirsten B Moysich; Douglas A Levine; Lambertus A Kiemeney; Leon F A G Massuger; Jacek Gronwald; Jan Lubiński; Anna Jakubowska; Cezary Cybulski; Louise Brinton; Jolanta Lissowska; Nicolas Wentzensen; Honglin Song; Valerie Rhenius; Ian Campbell; Diana Eccles; Weiva Sieh; Alice S Whittemore; Valerie McGuire; Joseph H Rothstein; Rebecca Sutphen; Hoda Anton-Culver; Argyrios Ziogas; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; Susan J Ramus; Celeste L Pearce; Malcolm C Pike; Daniel O Stram; Anna H Wu; Jolanta Kupryjanczyk; Agnieszka Dansonka-Mieszkowska; Iwona K Rzepecka; Beata Spiewankiewicz; Marc T Goodman; Lynne R Wilkens; Michael E Carney; Pamela J Thompson; Florian Heitz; Andreas du Bois; Ira Schwaab; Philipp Harter; Jacobus Pisterer; Peter Hillemanns; Beth Y Karlan; Christine Walsh; Jenny Lester; Sandra Orsulic; Stacey J Winham; Madalene Earp; Melissa C Larson; Zachary C Fogarty; Estrid Høgdall; Allan Jensen; Susanne Kruger Kjaer; Brooke L Fridley; Julie M Cunningham; Robert A Vierkant; Joellen M Schildkraut; Edwin S Iversen; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Irene Orlow; Tanja Pejovic; Yukie Bean; Claus Høgdall; Lene Lundvall; Ian McNeish; James Paul; Karen Carty; Nadeem Siddiqui; Rosalind Glasspool; Thomas Sellers; Catherine Kennedy; Yoke-Eng Chiew; Andrew Berchuck; Stuart MacGregor; Paul D P Pharoah; Ellen L Goode; Anna deFazio; Penelope M Webb; Georgia Chenevix-Trench
Journal:  Clin Cancer Res       Date:  2015-07-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.